^
Association details:
| Biomarker: | GNAQ mutation |
|---|---|
| Cancer: | Uveal Melanoma |
| Drug: | sotrastaurin (AEB071) (PKC inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Genomic Profiling of Metastatic Uveal Melanoma and Clinical Results of a Phase I Study of the Protein Kinase C Inhibitor AEB071
Excerpt:
Patients with metastatic UM (n = 153) were treated with AEB071 in a phase I, single-arm study. GNAQ/GNA11 mutations were observed at a similar frequency (93%) as previously reported, confirming a therapeutic window for inhibition of the downstream effector PKC in metastatic UM. In conclusion, the protein kinase C inhibitor AEB071 was well tolerated, and modest clinical activity was observed in metastatic UM.
DOI:
10.1158/1535-7163.MCT-19-0098
